Panion & Bf Biotech Inc. (1760.TW)
TWD 67.3
(2.75%)
TWD 67.3
(2.75%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 817.56 Million TWD | -16.45% |
| 2022 | 904.55 Million TWD | 21.46% |
| 2021 | 744.7 Million TWD | 5.47% |
| 2020 | 706.08 Million TWD | 10.26% |
| 2019 | 640.38 Million TWD | 8.28% |
| 2018 | 591.41 Million TWD | 7.6% |
| 2017 | 549.65 Million TWD | 19.79% |
| 2016 | 458.86 Million TWD | -25.5% |
| 2015 | 615.92 Million TWD | 13.08% |
| 2014 | 544.67 Million TWD | 20.79% |
| 2013 | 450.92 Million TWD | 13.97% |
| 2012 | 395.64 Million TWD | 13.32% |
| 2011 | 349.14 Million TWD | -0.03% |
| 2010 | 349.25 Million TWD | 19.08% |
| 2009 | 293.29 Million TWD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 204.52 Million TWD | 1.98% |
| 2024 Q1 | 224.05 Million TWD | 18.07% |
| 2023 Q4 | 189.75 Million TWD | -8.49% |
| 2023 FY | 755.73 Million TWD | -16.45% |
| 2023 Q1 | 205.26 Million TWD | -14.58% |
| 2023 Q2 | 198.2 Million TWD | -3.44% |
| 2023 Q3 | 207.35 Million TWD | 4.61% |
| 2022 Q1 | 188.07 Million TWD | 3.76% |
| 2022 Q3 | 231.44 Million TWD | -5.43% |
| 2022 Q4 | 240.29 Million TWD | 3.82% |
| 2022 FY | 904.55 Million TWD | 21.46% |
| 2022 Q2 | 244.72 Million TWD | 30.12% |
| 2021 Q3 | 199.72 Million TWD | 3.66% |
| 2021 Q4 | 181.26 Million TWD | -9.24% |
| 2021 FY | 744.7 Million TWD | 5.47% |
| 2021 Q1 | 171.03 Million TWD | -23.72% |
| 2021 Q2 | 192.67 Million TWD | 12.65% |
| 2020 Q4 | 224.23 Million TWD | 33.3% |
| 2020 Q1 | 155.95 Million TWD | -14.79% |
| 2020 Q3 | 168.22 Million TWD | 6.69% |
| 2020 FY | 706.08 Million TWD | 10.26% |
| 2020 Q2 | 157.67 Million TWD | 1.11% |
| 2019 FY | 640.38 Million TWD | 8.28% |
| 2019 Q4 | 183.01 Million TWD | 23.77% |
| 2019 Q1 | 145.82 Million TWD | -18.67% |
| 2019 Q3 | 147.87 Million TWD | -9.65% |
| 2019 Q2 | 163.66 Million TWD | 12.23% |
| 2018 Q1 | 124.68 Million TWD | -18.65% |
| 2018 FY | 591.41 Million TWD | 7.6% |
| 2018 Q4 | 179.3 Million TWD | 24.53% |
| 2018 Q3 | 143.98 Million TWD | 0.32% |
| 2018 Q2 | 143.53 Million TWD | 15.12% |
| 2017 Q1 | 123.98 Million TWD | 3.07% |
| 2017 Q2 | 129.39 Million TWD | 4.37% |
| 2017 Q3 | 143.01 Million TWD | 10.53% |
| 2017 FY | 549.65 Million TWD | 19.79% |
| 2017 Q4 | 153.26 Million TWD | 7.16% |
| 2016 Q2 | 115.39 Million TWD | 0.0% |
| 2016 Q4 | 120.28 Million TWD | 9.01% |
| 2016 Q3 | 110.34 Million TWD | -4.37% |
| 2016 FY | 458.86 Million TWD | -25.5% |
| 2016 Q1 | 115.39 Million TWD | -26.91% |
| 2015 FY | 615.92 Million TWD | 13.08% |
| 2015 Q4 | 157.88 Million TWD | 0.0% |
| 2015 Q3 | 157.88 Million TWD | 3.83% |
| 2015 Q2 | 152.06 Million TWD | 0.0% |
| 2015 Q1 | 152.06 Million TWD | 2.94% |
| 2014 Q2 | 119.8 Million TWD | 0.0% |
| 2014 FY | 544.67 Million TWD | 20.79% |
| 2014 Q1 | 119.8 Million TWD | 2.06% |
| 2014 Q4 | 147.72 Million TWD | 0.0% |
| 2014 Q3 | 147.72 Million TWD | 23.3% |
| 2013 Q3 | 117.38 Million TWD | 16.24% |
| 2013 Q4 | 117.38 Million TWD | 0.0% |
| 2013 FY | 450.92 Million TWD | 13.97% |
| 2013 Q1 | 100.97 Million TWD | -8.09% |
| 2013 Q2 | 100.97 Million TWD | 0.0% |
| 2012 FY | 395.64 Million TWD | 13.32% |
| 2012 Q3 | 109.86 Million TWD | 0.0% |
| 2012 Q4 | 109.86 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | 349.14 Million TWD | -0.03% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | 349.25 Million TWD | 19.08% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 293.29 Million TWD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Apex Biotechnology Corp. | 389.4 Million TWD | -109.956% |
| Sinphar Pharmaceutical Co.,Ltd. | 807.86 Million TWD | -1.201% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 437.58 Million TWD | -86.837% |
| GenMont Biotech Incorporation | 204.2 Million TWD | -300.368% |
| Abnova (Taiwan) Corporation | 126.72 Million TWD | -545.172% |
| Adimmune Corporation | 1.13 Billion TWD | 27.884% |
| Tanvex BioPharma, Inc. | 2.16 Billion TWD | 62.158% |
| Polaris Group | -3.06 Million TWD | 26774.323% |
| Energenesis Biomedical CO.,LTD. | 267.06 Million TWD | -206.132% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -4468.185% |
| PELL Bio-Med Technology Co. Ltd. | 385.1 Million TWD | -112.297% |